Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?

Podobne knjige/članki

• Sirolimus, tacrolimus and low-dose methotrexate as graft versus host disease prophylaxis in related and unrelated donor reduced intensity conditioning allogeneic peripheral blood stem cell transplantation
  od: Alyea, Edwin P., et al.
  Izdano: (2008)
• Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
  od: Koreth, John, et al.
  Izdano: (2009)
• Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft‐versus‐host disease prophylaxis
  od: Garming Legert, Karin, et al.
  Izdano: (2020)
• Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation
  od: Koreth, John, et al.
  Izdano: (2012)
• Cyclosporine Plus Methotrexate or Cyclosporine Plus Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Acute Leukemia Transplant: Comparison of Toxicity, Engraftment Kinetics and Transplant Outcome
  od: Gupta, Alok, et al.
  Izdano: (2015)